Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good Morning Chart and WU!
Good Morning Chart and WU!
Good Morning Chart and WU!
Good Morning Chart and WU
Good Morning Chart and WU!
Good Morning Chart and WU!
Your next post will be ignored just like this one will be.
Good Morning Chart and WU!
Good Morning Chart and WU!
INIX .04 + 220%
INIX .03 up 140%
INIX on the run .025
The ignore tag is a great way to do away with them.
Good Morning Chart and WU - Prayers to you Chart
66 million buy 79 million on the sells
Good Morning Chart and WU!
Good Morning Chart and WU!
44 million buy vol.----32 million sell vol.
Sorry, fat fingers, should be WU
Happy Thanksgiving Chart and WY!
Good Morning Chart and WU. Glad to hear the great news!
Good Morning Chart, sorry to hear about your mom , my prayers are with you.
Good Morning Chart and WU!
Good Morning Chart and WU!
Good Morning Chart and WU!
Good Morning Chart and WU!
BIEL Quarterly report http://www.pinksheets.com/otciq/ajax/sho...
Good Morning Chart and WU!
Happy Birthday Chart - hope you have a great one!
Sheff--> FDA head to speed reviews and clean up problems in the division that oversees drugs and medical devices.
http://www.reuters.com/article/Health09/idUSTRE5AB5F820091112
BIEL Trading Outlook for BioElectronics Corporation Issued by StockPreacher.com DALLAS, Nov. 12, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring BioElectronics Corporation (Pink Sheets:BIEL - News). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
Related Quotes
Symbol Price Change
BIEL.PK 0.0870 -0.0052
The investment report on BioElectronics Corporation (Pink Sheets:BIEL - News) should be of particular interest to comparable healthcare products providers: Johnson & Johnson (NYSE:JNJ - News), Pfizer (NYSE:PFE - News) and Bayer Aktienges (Pink Sheets:BAYRY - News).
The full report is available at: http://www.stockpreacher.com/n/BIEL
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
BioElectronics Corporation is the maker of innovative, patented, drug-free, over-the-counter, anti-inflammation medical devices and patches. The Company's novel approach to pain relief includes a wafer-thin patch containing a microchip and battery that produces pulsed electromagnetic energy, which has proved as an effective and superior method of safe relief of inflammation and pain following injury or invasive medical procedures. The Company markets its present products under the brand names ActiPatch(TM) and RecoveryRX(TM).
Message Board Search for BIEL: http://www.boardcentral.com/boards/BIEL
In the report, the analyst notes:
"The Company's dermal patch pain relief system is an innovative approach to anti-inflammation, which is estimated to address an approximate 400 million number of incidents of acute inflammation conditions each year. The market for anti-inflammation products is anticipated to grow beyond the current $10 billion market worldwide.
"The Company's products have entered Food and Drug Administration (FDA) clinical trials for various and wide number of conditions which have high probabilities of approval. Data released by the Company for the relief of heal and foot pain show a high degree of efficacy, providing widespread optimism and speculation of imminent FDA approval of the Company's Allay(TM) product. According to research firm Alquemie Partners LLC, approval of Allay(TM) could increase the Company's market capitalization to between $300 million and $500 million."
To read the entire report visit: http://www.stockpreacher.com/n/BIEL
BIEL (.10) +8%
Good Morning Chart and WU!
Thanks Chart! That is VERY interesting.
BIEL .09 up 24%
That's the million dollar question. I have a friend who uses their product and he swears by it. He found out about it through a friend of his who had good results. They have also entered into the veterinarian area recently.
BIEL (.088)
Speculators Betting on BioElectronics' Upcoming Study Results
Press Release
Source: BioMedReports.Com
On 11:46 am EST, Wednesday November 11, 2009
Companies:Bioelectronics Corporation
LOS ANGELES, CA--(Marketwire - 11/11/09) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, reports that investors are betting that BioElectronics' (Pinksheets:BIEL - News) upcoming medical study results will be significant.
The fact that a U.S. Food and Drug Administration advisory panel and federal regulators have taken aim at over-the-counter (OTC) acetaminophen products is not just the stuff of recent headlines. In fact, since as far back as 1977, FDA advisers have recommended explicit warnings not to exceed the dose or take acetaminophen for more than 10 days "because severe liver damage may occur." Back then, the FDA never followed that advice although they pledged to quickly consider its advisers' recommendations.
The pendulum has finally swung and now the agency is going out of its way to educate the public after official studies found that many people consume more than the recommended dose of these pain relievers in the mistaken belief that taking more will prove more effective against pain without posing health risks.
That push and the results of a soon to be released study by BioElectronics Corp. (Pinksheets:BIEL - News) set the table for an intriguing penny play in the coming days. With investors riding the wave of excitement about BIEL's technology and pending FDA decisions, the upcoming news flash will likely make shares of the micro-cap company run up again.
Company officials won't yet officially disclose what the study results will reveal, but there are strong hints in what was released as part of the pilot section of the study last month. That Institutional Review Board (IRB) supervised study is directed at comparing the effects of the company's ActiPatch� Therapy to acetaminophen in the form of Extra Strength Tylenol� for the treatment of delayed onset muscle soreness (DOMS).
The complete report is available now at BioMedReports.Com:
http://biomedreports.com/articles/most-popular/17424-banking-on-biels-upcoming-study-results-against-tylenol.html
Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
About BioMedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.
For more biomedical sector and investment news go to http://BioMedReports.com
BIEL (.0835) up 15%
Good Morning Chart and WU!
Nice report on BIEL (.0725)---> http://biomedreports.com/articles/most-popular/17424-banking-on-biels-upcoming-study-results-against-tylenol.html